Vifor Pharma inks $340m deal with Angion Biomedica Inc.
Swiss drugmaker Vifor Pharma has licenced US and EU commercialisation rights of Angion Biomedicas experimental kidney drug ANG-3777.
Cell and gene therapy specialist Minaris expanding
Japanese CDMO Minaris Regenerative Medicine Co. Ltd will invest US$64.5m to expand its facilities in Europe and Asia.
Protein Brewery raise 22m in Series A
Lead investor Novo Growth has led a 22m Series A investment in The Protein Brewery, a Dutch company that is to supplement the market for protein alternatives by fungal protein.
Galecto raise US$85m in Nasdaq IPO
HBM portfolio company Galecto has raised US$85m through the placement of 5.67 million new shares at a price of US$15 per share at Nasdaq.
BI initiates Phase II testing of COVID-19 drug
Boehringer Ingelheim announced the start of Phase II studies of its oral TRPC6 blocker code-named BI 764198 in patients hospitalised for COVID-19.
3P Bio to manufacture SpyBiotech vaccine
British SpyBiotech has outsourced GMP manufacturing of its VLP vaccine platform to Navarra-based 3P Biopharmaceuticals.
Bioinvent AB licences BI-1206 to CASI Pharmaceuticals
Swedish BioInvent AB has licensed its anti-Fc?RllB antibody BI-1206 for $95m to CASI Pharmaceuticals for distribtion in the Greater China region
Transgene reports clinical results of TG4001 plus avelumab
Transgene SA has reported positive results of an exploratory Phase Ib/II study in HPV-16-positive cancers combining its cancer vaccine TG4001 with Merck KgaAs PD-L1 blocker avelumab.
Roche licences antiviral nucleoside from Atea
Roche AG has paid US$350 in cash to co.develop and market Atea Pharmaceuticals oral direct-acting antiviral, AT-527, to limit proliferation of SARS-CoV-2.
ADC company Araris Biotech raises CHF15.2m
New ADC company Araris Biotech has got backing by Pureos Bioventures and co-investors in a CHF15.2m seed round to develop a new class of antibody drug conjugates.
·